ReviewClinics in geriatric medicine2023
Neuropathology of the Common Forms of Dementia.
Review in Clinics in geriatric medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for primary care.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Guideline
- The Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for specialty care.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Guideline
- Autopsy findings in Alzheimer's disease clinical trial participants demonstrate a high frequency of off-target coexisting pathologic features.The journal of prevention of Alzheimer's disease · 2026Article
- Emerging New Pathways in Malignant Neoplasms and Neurodegenerative Disorders: Perspectives for Therapeutics.Cells · 2026Review
- The many meanings of Alzheimer's disease and why they matter for policy, research, and care.GeroScience · 2026Article
- Parkinson's disease dementia and hearing impairment, are they related? A UK biobank pilot analysis.Experimental brain research · 2026Article
- Plasma Autoantibodies Against Neurodegeneration-Related Antigens in Dementia and Elevated Chi3Li Autoantibodies in Mild Cognitive Impairment.Biomolecules · 2026Article
- Impact of cardiometabolic factors and AD plasma biomarkers on white matter hyperintensities volume in individuals with cognitive complaints from the global south.Neuroscience · 2026Article
- Should all MCI with Alzheimer's biological diagnosis receive anti-amyloid therapy?Cell death & disease · 2026Review
- In vivo growth trajectories of regional brain volumes in the Wistar rat.Neurobiology of aging · 2025Article
- Air pollution and Alzheimer's disease prevention: The science and a prevention plan.Journal of Alzheimer's disease : JAD · 2025Review
- Ambient Air Pollution and the Severity of Alzheimer Disease Neuropathology.JAMA neurology · 2025Article
- Diagnosis and Management of Dementia for the Nephrology Clinician: A Review.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2025Review
- Expression patterns of blood-based biomarkers of neurodegeneration and inflammation across adulthood in rhesus macaques.Experimental gerontology · 2025Article
- Lewy Body Dementia.Continuum (Minneapolis, Minn.) · 2024Review
- Neighborhood disadvantage reduces cognitive reserve independent of neuropathologic change.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Engineered Exosomes Containing microRNA-29b-2 and Targeting the Somatostatin Receptor Reduce Presenilin 1 Expression and Decrease the β-Amyloid Accumulation in the Brains of Mice with Alzheimer's Disease.International journal of nanomedicine · 2024Article
- Medium-Chain Triglycerides (MCTs) for the Symptomatic Treatment of Dementia-Related Diseases: A Systematic Review.Journal of nutrition and metabolism · 2024Review
- Epigenetics as a link between environmental factors and dementia risk.Journal of Alzheimer's disease reports · 2024Review
- Alcohol Use Disorder and Dementia: A Review.Alcohol research : current reviews · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Dementias encompass a range of debilitating neurologic conditions. Here, we summarize the neuropathology of common forms of dementia, focusing on Alzheimer disease (AD) and related dementias. AD is part of a spectrum of neurodegenerative diseases that consists of various protein inclusions (ie, proteinopathies) but other brain abnormalities are also related to dementia. Beta-amyloid and tau aggregates are hallmarks of AD. Other tissue substrates include Lewy bodies, TDP-43 inclusions, vascular brain lesions, and mixed pathologies. This review highlights the complexity of neurodegenerative and other disease substrates and summarizes topography of these lesions and concepts of mixed brain pathologies, resistance, and resilience.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.